OKYO vs. SABS, NKGN, DYAI, ESLA, CDTX, BCLI, CYTH, QNCX, TARA, and INAB
Should you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include SAB Biotherapeutics (SABS), NKGen Biotech (NKGN), Dyadic International (DYAI), Estrella Immunopharma (ESLA), Cidara Therapeutics (CDTX), Brainstorm Cell Therapeutics (BCLI), Cyclo Therapeutics (CYTH), Quince Therapeutics (QNCX), Protara Therapeutics (TARA), and IN8bio (INAB). These companies are all part of the "biological products, except diagnostic" industry.
SAB Biotherapeutics (NASDAQ:SABS) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
OKYO Pharma has lower revenue, but higher earnings than SAB Biotherapeutics.
OKYO Pharma has a net margin of 0.00% compared to OKYO Pharma's net margin of -1,884.10%. SAB Biotherapeutics' return on equity of 0.00% beat OKYO Pharma's return on equity.
In the previous week, OKYO Pharma had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for OKYO Pharma and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.00 beat OKYO Pharma's score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media.
SAB Biotherapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
SAB Biotherapeutics received 13 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 73.91% of users gave SAB Biotherapeutics an outperform vote.
SAB Biotherapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 264.71%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 376.16%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than SAB Biotherapeutics.
7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 26.0% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
OKYO Pharma beats SAB Biotherapeutics on 10 of the 15 factors compared between the two stocks.
Get OKYO Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OKYO Pharma Competitors List
Related Companies and Tools
